Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Gene replacement therapy is an attractive approach for treatment of genetic disease, but may be complicated by the risk of a neutralizing immune response to the therapeutic gene product. There are examples of humoral and cellular immune responses against the transgene product as well as absence of such responses, depending on vector design and the underlying mutation in the dysfunctional gene. It has been unclear, however, whether transgene expression can induce tolerance to the therapeutic antigen. Here, we demonstrate induction of immune tolerance to a secreted human coagulation factor IX (hF.IX) antigen by adeno-associated viral gene transfer to the liver. Tolerized mice showed absence of anti-hF.IX and substantially reduced in vitro T cell responses after immunization with hF.IX in adjuvant. Tolerance induction was antigen specific, affected a broad range of Th cell subsets, and was favored by higher levels of transgene expression as determined by promoter strength, vector dose, and mouse strain. Hepatocyte-derived hF.IX expression induced regulatory CD4(+) T cells that can suppress anti-hF.IX formation after adoptive transfer. With a strain-dependent rate of success, tolerance to murine F.IX was induced in mice with a large F.IX gene deletion, supporting the relevance of these data for treatment of hemophilia B and other genetic diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“mouse studies have shown liver-directed AAV gene therapy results in tolerogenic responses by the induction of Tregs,52, 53, 54, 55, 56, 57, 58, 59”
From Modulating immune responses to AAV by expanded polyclonal T-regs and capsid specific chimeric antigen receptor T-regulatory cells (2021) · cites this paper as [53]
The cited source says what the claim attributes to it.
In the citing paper
“It has been shown in multiple preclinical (160, 168 -171) and clinical studies (34) that liver-targeted AAV delivery induced immune tolerance of transgene products.”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [34]
In the citing paper
“The immunogenic i.m. route was chosen for these experiments, as hepatic gene transfer typically results in tolerance induction to FIX (24, 38).”
From Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy (2021) · cites this paper as [24]
In the citing paper
“Expression of DTR under XCR1 promoter allowed specific depletion of XCR1+ DCs by administration of diphtheria toxin (DT) whereas expression of fluorescent protein allowed their easy detection and tracking.”
From Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy (2021) · cites this paper as [24]
In the citing paper
“Fortunately, the immune response is not always against AAV-mediated gene transfer, evidenced by induction of regulatory T cells (Tregs) that suppress immune response and facilitate sustained transgene expression (34, 35).”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [34]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dendritic Cell Subsets and Lineages, and Their Functions in Innate and Adaptive Immunity
Liu, Y.-J. (2001) · Cell · doi:10.1016/s0092-8674(01)00456-1 · Cited by 1,004
Self-citationInduction and mechanism of action of transforming growth factor‐β‐secreting Th3 regulatory cells
Weiner, H. L. (2001) · Immunological Reviews · doi:10.1034/j.1600-065x.2001.1820117.x · Cited by 846 · cited 7×
“We do not know at this point whether TGF-β in hepatic tolerance is derived from regulatory Th3 cells or a different cell type.”
BackgroundInfluentialRoncarolo, M. G., Bacchetta, R., Bordignon, C., Narula, S., & Levings, M. K. (2001) · Immunological Reviews · doi:10.1034/j.1600-065x.2001.1820105.x · Cited by 814 · cited 6×
“We do not know at this point whether TGF-β in hepatic tolerance is derived from regulatory Th3 cells or a different cell type.”
BackgroundInfluentialLimmer, A., Ohl, J., Kurts, C., Ljunggren, H.-G., Reiss, Y., Groettrup, M., Momburg, F., Arnold, B., & Knolle, P. A. (2000) · Nature Medicine · doi:10.1038/82161 · Cited by 758 · cited 1×
“Liver transplants are often not rejected even across MHC barriers, and LSECs have been shown to represent specialized APCs that can induce T cell tolerance (40, 42).”
BackgroundLocal control of the immune response in the liver
Knolle, P. A., & Gerken, G. (2000) · Immunological Reviews · doi:10.1034/j.1600-0528.2002.017408.x · Cited by 603 · cited 3×
“) promotes tolerance rather than immunity to the transgene product (40).”
BackgroundSnyder, R. O., Miao, C. H., Patijn, G. A., Spratt, S. K., Danos, O., Nagy, D., Gown, A. M., Winther, B., Meuse, L., Cohen, L. K., et al. (1997) · Nature Genetics · doi:10.1038/ng0797-270 · Cited by 579
Herzog, R. W., Yang, E. Y., Couto, L. B., Hagstrom, J. N., Elwell, D., Fields, P. A., Burton, M., Bellinger, D. A., Read, M. S., Brinkhous, K. M., et al. (1999) · Nature Medicine · doi:10.1038/4743 · Cited by 554 · cited 3×
“IX vectors to adults with severe hemophilia B were initiated (4, 5, 8, 9).”
BackgroundSelf-citationAdeno-associated virus vectors can be efficiently produced without helper virus
Matsushita, T., Elliger, S., Elliger, C., Podsakoff, G., Villarreal, L., Kurtzman, G., Iwaki, Y., & Colosi, P. (1998) · Gene Therapy · doi:10.1038/sj.gt.3300680 · Cited by 500 · cited 1×
“AAV vector (serotype 2) was produced by triple transfection of HEK-293 cells, purified by CsCl-gradient centrifugation, and quantitated by dot blot hybridization as described (23).”
MethodNakai, H., Yant, S. R., Storm, T. A., Fuess, S., Meuse, L., & Kay, M. A. (2001) · Journal of Virology · doi:10.1128/jvi.75.15.6969-6976.2001 · Cited by 478 · cited 1×
“IX as designed by Kay and colleagues (22).”
MethodJooss, K., Yang, Y., Fisher, K. J., & Wilson, J. M. (1998) · Journal of Virology · doi:10.1128/jvi.72.5.4212-4223.1998 · Cited by 470 · cited 5×
“Even with a ubiquitous promoter, hepatocytes are the major site of F.IX synthesis following portal infusion of AAV vector, which has a strong tropism for liver and does not appear to transduce other cell types within the liver or APCs (24, 43, 44).”
BackgroundInfluential
Research works printed but not linked: 2
- Manno, C.S., et al. 2003. A phase I safety study in patients with severe hemophilia B using adeno-associated viral (AAV) vector to deliver the gene for human factor IX to skeletal muscle. Blood . In press.
- Nakai, H., et al. 2000. A proposed rAAV-liver directed clinical trial for hemophilia B. Blood. 96 (Suppl.):798a-799a.
Cited by
Items 301–400 of 471
Tolerance induction in hemophilia: innovation and accomplishments
Sherman, A., Biswas, M., & Herzog, R. W. (2018) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000446 · Cited by 18
Self-citationLeger, A. J., Mosquea, L. M., Li, L., Chuang, W., Pacheco, J., Taylor, K. M., Luo, Z., Piepenhagen, P. A., Ziegler, R. J., Moreland, R. J., et al. (2011) · The Journal of Gene Medicine · doi:10.1002/jgm.1575 · Cited by 17
“mediated liver‐restricted expression of a foreign protein induces tolerance in immunocompetent mice [12,14].”
BackgroundCremel, M., Guérin, N., Campello, G., Barthe, Q., Berlier, W., Horand, F., & Godfrin, Y. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.05.062 · Cited by 17
Feng, Y., Jacobs, F., Craeyveld, E. V., Lievens, J., Snoeys, J., Linthout, S. V., & Geest, B. D. (2009) · Gene Therapy · doi:10.1038/gt.2009.125 · Cited by 16
Suppression of pullulanase-induced cytotoxic T cell response with a dual promoter in GSD IIIa mice
Lim, J., Kishnani, P. S., & Sun, B. (2022) · JCI Insight · doi:10.1172/jci.insight.152970 · Cited by 16
L. Rogers, G., & E. Hoffman, B. (2013) · Journal of Genetic Syndromes & Gene Therapy · doi:10.4172/2157-7412.s1-012 · Cited by 16
“Some mice received vector via tail vein or splenic capsule injection of 1011 vg in order to transduce hepatic tissue, as previously described [8,9].”
MethodKumar, S. R. P., Xie, J., Hu, S., Ko, J., Huang, Q., Brown, H. C., Srivastava, A., Markusic, D. M., Doering, C. B., Spencer, H. T., et al. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.08.001 · Cited by 16
“This is in contrast to studies in mice that have shown greater capacity for immune tolerance induction to hFIX at higher vector doses/levels of expression.(26,27) Inhibitors against hFIX have been described for hepatic AAV gene transfer studies in non-human primates.”
MethodResultSelf-citationRETRACTED: Progress and prospects of skin gene therapy: a ten year history
Hengge, U. R. (2005) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2004.09.008 · Cited by 16
“[77] Mingozzi F, Liu YL, Dobrzynski E, et al.”
BackgroundRetractedCurrent and Emerging Issues in Adeno-Associated Virus Vector-Mediated Liver-Directed Gene Therapy
Piccolo, P., & Brunetti‐Pierri, N. (2025) · Human Gene Therapy · doi:10.1089/hum.2024.179 · Cited by 17
Kamala, O., Malik, T. H., Hallam, T. M., Cox, T. E., Yang, Y., Vyas, F., Luli, S., Connelly, C., Gibson, B. G., Smith‐Jackson, K., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.752916 · Cited by 17
Advances in Overcoming Immune Responses following Hemophilia Gene Therapy
H. Miao, C. (2012) · Journal of Genetic Syndromes & Gene Therapy · doi:10.4172/2157-7412.s1-007 · Cited by 15
“Hepatic gene transfer by AAV vectors resulting in persistent gene expression has been successfully used to induce immune tolerance to FVIII or FIX with or without transient immune suppression [66,67].”
MethodCohn, E. F., Zhuo, J., Kelly, M., & Chao, H. (2007) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2007.02522.x · Cited by 17
Genetic analysis of the antibody response to AAV2 and factor IX
Zhang, H., High, K. A., Wu, Q., Yang, P., Schlachterman, A., Yu, S., Yi, N., Hsu, H., & Mountz, J. D. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.02.014 · Cited by 15
Self-citationPuppi, J., Guillonneau, C., Pichard, V., Bellodi‐Privato, M., Cuturi, M. C., Anegón, I., & Ferry, N. (2004) · Journal of Hepatology · doi:10.1016/s0168-8278(04)00172-2 · Cited by 18
Immune tolerance induction by hepatic gene transfer: First-in-human evidence
Kaczmarek, R., Samelson‐Jones, B. J., & Herzog, R. W. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.03.016 · Cited by 15
Self-citationChoi, S. J., Yi, J. S., Lim, J., Tedder, T. F., Koeberl, D. D., Jeck, W. R., Desai, A. K., Rosenberg, A. S., Sun, B., & Kishnani, P. S. (2023) · The Journal of Gene Medicine · doi:10.1002/jgm.3509 · Cited by 14
Knolle, P. A., Huang, L., Kosinska, A. D., Wohlleber, D., & Protzer, U. (2021) · Vaccines · doi:10.3390/vaccines9111333 · Cited by 15
“Finally, continuous exposure towards antigens expressed in the liver for prolonged periods of time is associated with development of immune tolerance, which includes generation of regulatory immune cell populations [52].”
BackgroundGene therapy – are we ready now?
Kaczmarek, R. (2022) · Haemophilia · doi:10.1111/hae.14530 · Cited by 15
Muñoz-Melero, M., & Biswas, M. (2024) · Human Gene Therapy · doi:10.1089/hum.2023.227 · Cited by 14
“55 This correlated with the induction of Tregs and a lack of cellular or adaptive responses directed toward the transgene.”
Structure of the AAVhu.37 capsid by cryoelectron microscopy
Kaelber, J. T., Yost, S. A., Webber, K., Firlar, E., Liu, Y., Danos, O., & Mercer, A. C. (2020) · Acta Crystallographica Section F Structural Biology Communications · doi:10.1107/s2053230x20000308 · Cited by 15
“While hepatic gene transfer can induce immunity to the transferred gene (Dobrzynski et al., 2006), hepatic gene transfer with AAV can induce immune tolerance (Mount et al., 2002; Mingozzi et al., 2003; Breous et al., 2009, 2011), even when the gene transfer is not systemic (Martino et al., 2009).”
BackgroundSelf-citationStaunch protections: the ethics of haemophilia gene transfer research
Kimmelman, J. (2007) · Haemophilia · doi:10.1111/j.1365-2516.2007.01567.x · Cited by 14
Clinical perspective: Advancing hemophilia treatment through gene therapy approaches
Thornburg, C. D., PIPE, S. W., Cantore, A., Unzu, C., Jones, M., & Miesbach, W. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.04.023 · Cited by 13
Cardiac Gene Therapy: From Concept to Reality
Kratlian, R. G., & Hajjar, R. J. (2011) · Current Heart Failure Reports · doi:10.1007/s11897-011-0077-1 · Cited by 15
Adding recombinant AAVs to the cancer therapeutics mix
Mulcrone, P. L., Herzog, R. W., & Xiao, W. (2022) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2022.09.009 · Cited by 13
Self-citationEmerging approaches to induce immune tolerance to therapeutic proteins
Noel, J. C., Lagassé, D., Golding, B., & Sauna, Z. E. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.10.002 · Cited by 13
Li, Z., Jayandharan, G. R., Aslanidi, G., Zolotukhin, S., Herzog, R. W., & Srivastava, A. (2012) · Journal of Genetic Syndromes & Gene Therapy · doi:10.4172/2157-7412.s1-008 · Cited by 16
“IX after hepatic gene transfer with AAV2 vector [37-39].”
BackgroundInduction of Immune Tolerance to a Therapeutic Protein by Intrathymic Gene Delivery
Chu, Q., Moreland, R. J., Gao, L., Taylor, K. M., Meyers, E., Cheng, S. H., & Scheule, R. K. (2010) · Molecular Therapy · doi:10.1038/mt.2010.164 · Cited by 13
Genetic Modification of Donor Hepatocytes Improves Therapeutic Efficacy for Hemophilia B in Mice
Wu, Y., Kao, C., Huang, Y., Yu, I., Lee, M., Lai, H., Lee, P., Lin, C., & Lin, S. (2010) · Cell Transplantation · doi:10.3727/096368910x503398 · Cited by 14
Shi, Y., Falahati, R., Zhang, J., Flebbe-Rehwaldt, L., & Gaensler, K. M. L. (2013) · Gene Therapy · doi:10.1038/gt.2013.22 · Cited by 15
Helper-dependent adenoviral vectors
Brunetti‐Pierri, N., & Ng, P. (2010) · Springer eBooks · doi:10.1007/978-3-0346-0165-8_13 · Cited by 14
Gottrand, G., Taleb, K., Ragon, I., Bergot, A., Goldstein, J. D., & Marodon, G. (2012) · The Journal of Gene Medicine · doi:10.1002/jgm.1650 · Cited by 13
“administration of an AAV encoding factor IX (mutations of which are responsible for hemophilia B) [30].”
BackgroundGene therapy for treatment of inherited haematological disorders
Herzog, R. W., Cao, O., Hagstrom, J. N., & Wang, L. (2006) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.6.5.509 · Cited by 15
Self-citationProfile of efraloctocog alfa and its potential in the treatment of hemophilia A
Camire, R. M., & George, L. A. (2015) · Journal of Blood Medicine · doi:10.2147/jbm.s54632 · Cited by 14
“Importantly, prior work has demonstrated that liver-directed gene therapy has the capacity to induce transgene tolerance.(66,67) Notably, this has specifically been demonstrated for AAV- mediated FVIII gene transfer in canine models hemophilia A.”
Evading the AAV Immune Response in Mucopolysaccharidoses
Piechnik, M., Sawamoto, K., Ohnishi, H., Kawamoto, N., Ago, Y., & Tomatsu, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103433 · Cited by 12
Tolerance to MHC class II disparate allografts through genetic modification of bone marrow
Jindra, P., Tripathi, S., Tian, C., Iacomini, J., & Bagley, J. (2012) · Gene Therapy · doi:10.1038/gt.2012.57 · Cited by 12
“There has been a great deal of interest in using gene therapy to induce a state of tolerance in the context of restoring normal immune responses in autoimmune models (35-46), in eliminating immune responses to introduced transgenes in the context of replacement gene therapy (47-49), and in inducing tolerance to allerg…”
Special lectures in haemophilia management
Bátorová, A., High, K. A., & Gringeri, A. (2010) · Haemophilia · doi:10.1111/j.1365-2516.2010.02289.x · Cited by 13
Self-citationPicanço‐Castro, V., Russo, E. M. D. S., Fontes, A. M., Fernandes, A. C., & Covas, D. T. (2008) · Genetics and Molecular Research · doi:10.4238/vol7-2gmr447 · Cited by 11
“The murine albumin promoter-enhancer has been shown to drive factor IX expression in recipient animals for up to six months (Mingozzi et al., 2003).”
BackgroundSimmons, E. M., Wen, Y., Li, J., Qian, Y., Wong, L. C., Konrad, R. J., & Bivi, N. (2022) · Journal of Immunological Methods · doi:10.1016/j.jim.2022.113397 · Cited by 11
Immunocompetent nontransgenic mouse models for studying hepatitis B virus immune responses
Tzeng, H.-T., Hsu, P., & Chen, P. (2013) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12035 · Cited by 11
Gene therapy for lysosomal storage disorders
Cresawn, K. O., & Byrne, B. J. (2005) · Laboratory techniques in biochemistry and molecular biology · doi:10.1016/s0075-7535(05)31010-2 · Cited by 11
VandenDriessche, T., & Chuah, M. (2011) · Human Gene Therapy · doi:10.1089/hum.2011.221 · Cited by 11
“This may reflect the ability of the FIX-transduced hepatocytes to induce immune tolerance against the transgene product (Mingozzi et al ., 2003).”
Induction of factor VIII tolerance by hemophilia gene transfer to eradicate factor VIII inhibitors
Young, G. A. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024013000 · Cited by 10
FLT201, a novel liver-directed AAV gene therapy candidate for Gaucher disease type 1
Comper, F., Miranda, C. J., Liou, B., Dodev, T. S., Jeyakumar, J. M., Canavese, M., Cocita, C., Khoshrou, K., Tiscórnia, G., Chisari, E., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.05.003 · Cited by 11
“46 Additionally, targeting the liver for transgene expression is associated with immune tolerance, partly due to the induction of antigen-specific regulatory T cells.”
Immune Toxicities in AAV Gene Therapy: Overview for Clinicians
Parajuli, S., Gallagher, T. L., & Flotte, T. R. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27073196 · Cited by 12
“Following these initial findings in the AAV2-FIX trial, monitoring of capsid-directed T cell responses has been implemented in other muscle gene transfer clinical trials [38], which found a dose-dependent relationship between the vector and the activation of capsid-specific T cell responses.”
Sack, B. K., Wang, X., Sherman, A., Rogers, G. L., & Markusic, D. M. (2014) · Haemophilia · doi:10.1111/hae.12522 · Cited by 10
Batista, A. R., Gianni, D., Ventosa, M., Coelho, A. V., Almeida, M. R., Sena‐Esteves, M., & Saraiva, M. J. (2014) · Gene Therapy · doi:10.1038/gt.2014.86 · Cited by 12
Coaxing the liver into preventing autoimmune disease in the brain
Hoffman, B. E., & Herzog, R. W. (2008) · Journal of Clinical Investigation · doi:10.1172/jci37079 · Cited by 12
Self-citationVandenDriessche, T. (2009) · Human Gene Therapy · doi:10.1089/hum.2009.1007 · Cited by 9
“Nevertheless, it is reassuring that gene therapy also provides a way to prevent or even suppress immune responses directed at the therapeutically relevant protein encoded by the gene delivery vector, for instance, through induction of regulatory T cells (Mingozzi et al., 2003).”
Recino, A., Gan, S. U., Sia, K. C., Sawyer, Y., Trendell, J., Kay, R. G., Gribble, F. M., Reimann, F., Foale, R., Notaridou, M., et al. (2018) · Gene Therapy · doi:10.1038/s41434-018-0052-5 · Cited by 10
“Previous studies have shown that AAV-mediated expression in the liver can facilitate immune tolerance to clotting factors in mice [44], and, perhaps of greater importance to our present study,”
BackgroundBrown, B. D., Venneri, M. A., Zingale, A., Sergi, L. S., & Naldini, L. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.08.1224 · Cited by 9
Chan, C.-C., Lai, C., Wu, C.-J., Chen, L., Tao, M., & Kuo, M. (2016) · Human Gene Therapy · doi:10.1089/hum.2015.161 · Cited by 9
“7,48,49 The AAV8 serotype preferentially targets the liver to support sustained transgene products and induce active tolerogenic responses.”
Identification of novel drug targets for the treatment of heart failure
Moilanen, A. (2012) · Cited by 8
Unlocking Transplant Tolerance with Biomaterials
Pham, J. A., & Coronel, M. M. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202400965 · Cited by 9
Gene therapy for hemophilia: advancing beyond the first clinical success
Monahan, P. E., & Gui, T. (2013) · Current Opinion in Hematology · doi:10.1097/moh.0b013e328363c1a1 · Cited by 9
Deng, M., Zhou, H., He, S., Qiu, H., Wang, Y., Zhao, A. Y., Mu, Y., Li, F., & Zhao, A. Z. (2023) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-023-02894-0 · Cited by 8
“…that mice expressing human factor IX in the liver are immune to transgenic products, several studies using AAV vectors in small and large animal models of genetic disease have shown that expression of the antigen in hepatocytes can promote strong antigen-specific immune tolerance [50–52].”
BackgroundSelf-citationIizuka, S., Sakurai, F., Tachibana, M., Ohashi, K., & Mizuguchi, H. (2017) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2017.07.001 · Cited by 8
“Adeno-associated virus (AAV) vector-mediated liver-specific hFIX expression using an AHA promoter in adult mice efficiently induced immune tolerance to hFIX, while ubiquitous expression of hFIX using a human elongation factor-1 alpha (EF-1a) promoter resulted in efficient induction of immune responses to hFIX.(24) The…”
BackgroundPark, F., & Gow, K. W. (2006) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2006.05.003 · Cited by 8
Is dystrophin immunogenicity a barrier to advancing gene therapy for Duchenne muscular dystrophy?
Górecki, D. C., Kaliński, P., & Pomeroy, J. (2025) · Gene Therapy · doi:10.1038/s41434-025-00531-y · Cited by 9
“Systemic delivery might provoke a faster and more widespread immune response than some forms of localised delivery, while liver targeting may be associated with the liver tolerance effect to antigens [62, 63].”
Factor VIII: Perspectives on Immunogenicity and Tolerogenic Strategies for Hemophilia A Patients.
Khalilian, S., Motovali-Bashi, M., & Rezaie, H. (2020) · PubMed Central · doi:10.22088/ijmcm.bums.9.1.33 · Cited by 8
“Due to the ideal characteristics of liver for the induction of immune tolerance, including lower innate immune response, inflammatory environment, and professional APCs formation in the liver, hepatic gene transfer is an appropriate destination for different types of AAV vectors with the lowest danger of protective im…”
BackgroundLevin, D., Lagassé, H. A. D., Burch, E. E., Strome, S. E., Tan, S., Jiang, H., Sauna, Z. E., & Golding, B. (2017) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13649 · Cited by 7
Rana, J., Marsic, D., Zou, C., Muñoz-Melero, M., Li, X., Kondratov, O., Li, N., de Jong, Y. P., Zolotukhin, S., & Biswas, M. (2023) · Human Gene Therapy · doi:10.1089/hum.2022.176 · Cited by 9
Wang, D., Worsham, D. N., & Pan, D. (2007) · The Journal of Gene Medicine · doi:10.1002/jgm.1141 · Cited by 7
“The endogenous levels of MGMT protein varies among different tissues (by 100-fold), with the highest levels found in the liver and the lowest in bone marrow [34,35].”
BackgroundGenomic Designs of rAAVs Contribute to Pathological Changes in the Livers and Spleens of Mice
Mulcrone, P. L., Zhang, J., Pride, P. M., Lam, A. K., Frabutt, D. A., Ball-Kell, S. M., & Xiao, W. (2022) · Advances in Cell and Gene Therapy · doi:10.1155/2022/6807904 · Cited by 7
Adeno‐associated viral vectors for gene therapy
Flotte, T. R., & Berns, K. I. (2005) · Laboratory techniques in biochemistry and molecular biology · doi:10.1016/s0075-7535(05)31001-1 · Cited by 7
“gene therapy vector‐derived expression (Chao and Walsh, 2001; Herzog et al., 2002; Mingozzi et al., 2003).”
BackgroundActivation of immune checkpoint OX40 inhibits HBV replication in a mouse model
Zhan, M., Zhong, S., Niu, J., & Gao, X. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114120 · Cited by 6
Acute intermittent porphyria: vector optimization for gene therapy
Yasuda, M., Domaradzki, M. E., Armentano, D., Cheng, S. H., Bishop, D. F., & Desnick, R. J. (2007) · The Journal of Gene Medicine · doi:10.1002/jgm.1074 · Cited by 6
Prospective therapeutic approaches in mitochondrial neurogastrointestinal encephalomyopathy (MNGIE)
Cabrera-Pérez, R., Torres‐Torronteras, J., Vila‐Julià, F., Ortega, F. J., Cámara, Y., Barquinero, J., & Martí, R. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2015.1090307 · Cited by 9
“However, transaminase rises were slight or mild, and the episode resolved after few weeks of prednisolone treatment [98,99,115].”
BackgroundGene Therapy in Pediatric Liver Disease
Muro, A. F., D’Antiga, L., & Mingozzi, F. (2019) · Springer eBooks · doi:10.1007/978-3-319-96400-3_44 · Cited by 7
Self-citationTreatment of Inhibitors in Hemophilia B
Brown, S. A. (2005) · Wiley eBooks · doi:10.1002/9780470987124.ch18 · Cited by 6
A Novel Murine Model Enabling rAAV8-PC Gene Therapy for Severe Protein C Deficiency
Levy‐Mendelovich, S., Avishai, E., Samelson‐Jones, B. J., Dardik, R., Brutman‐Barazani, T., Nisgav, Y., Livnat, T., & Kenet, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910336 · Cited by 5
“Previous murine models have been used for both hemophilia A [17,20] and B [11] to examine the feasibility of GT. Notably, both FVIII and FIX, which are pro-coagulant proteins produced in the liver, show a prominent similarity to PC, a natural anticoagulant, in terms of the ability of their partial…”
MethodAAV Vector-Based Gene Therapy, Progress and Current Challenges
Kuranda, K., & Mingozzi, F. (2017) · Springer eBooks · doi:10.1007/978-3-319-53457-2_5 · Cited by 5
Self-citationTrevisan, B., Rodriguez, M., Medder, H., Lankford, S. S., Combs, R., Owen, J., Atala, A., Porada, C. D., & Almeida-Porada, G. D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1070476 · Cited by 5
Brimble, M. A., Morton, C. L., Winston, S. M., Reeves, I. L., Spence, Y., Cheng, P.-H., Zhou, J., Nathwani, A. C., Thomas, P. G., Souquette, A. H., et al. (2024) · Human Gene Therapy · doi:10.1089/hum.2023.188 · Cited by 7
Dwivedi, S., Purohit, P., Mittal, Y., Gupta, G., Goel, A., Verma, R. C., Khattri, S., Sharma, P., Misra, S., & Pant, K. K. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804659-3.00022-1 · Cited by 7
Rajapaksha, I. G., Angus, P., & Herath, C. B. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.80317 · Cited by 7
“A follow-up study demonstrated an induction of immune tolerance in mice after hepatic gene transfer by rAAV expressing human FIX (rAAV-hFIX), which is mediated by regulatory CD4+ T cells, resulting in suppression of human FIX antibody formation [6, 98].”
BackgroundAssessment of Immune Responses Against AAV Encoded Transgene Products
Gorovits, B., Azadeh, M., Fiscella, M., Harrison, T., Hofer, M., Janetzki, S., Jawa, V., Long, B. R., Lu, Y., Mahnke, Y. D., et al. (2026) · The AAPS Journal · doi:10.1208/s12248-025-01192-w · Cited by 5
“The intravenous (IV) administration of the AAV vector allows for transduction of multiple tissues, including liver, and, based on the proposed immune tolerizing effect of the liver expressed transgene protein, may result in a reduced level of anti-TP immunity (11, 13, 81, 86, 87).”
Viral Vector Based Immunotherapy for Peanut Allergy
Gonzalez-Visiedo, M., Herzog, R. W., Muñoz-Melero, M., Blessinger, S. A., Cook‐Mills, J. M., Daniell, H., & Markusic, D. M. (2024) · Viruses · doi:10.3390/v16071125 · Cited by 5
“Approximately two decades ago, liver-directed gene therapy with adeno-associated viral (AAV) vectors emerged as a method of immune tolerance induction [1,2].”
BackgroundMethodInfluentialSelf-citationSingle-dose AAV vector gene immunotherapy to treat food allergy
Gonzalez-Visiedo, M., Li, X., Muñoz-Melero, M., Kulis, M. D., Daniell, H., & Markusic, D. M. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.07.008 · Cited by 5
“In mice presensitized to OVA, we found that the AAV8-EF1a-OVA vector was more effective in suppressing allergic symptoms, which is contradictory to previous studies demonstrating that hepatic restricted expression of an antigen is more effective at inducing immune tolerance.(48) However, these studies used an AAV2 cap…”
ResultRapti, K., Hajjar, R. J., & Weber, T. (2012) · Humana Press eBooks · doi:10.1007/978-1-61779-891-7_12 · Cited by 4
Wang, Q., Zhang, L., Zhang, G., Mao, J.-H., Xi, X., Jiang, L., Lv, G., Lu, J., Shen, Y., Chen, Z., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2110887118 · Cited by 4
Gene-based continuous expression of FVIIa for the treatment of hemophilia
Margaritis, P. (2011) · Frontiers in Bioscience-Scholar · doi:10.2741/269 · Cited by 5
“Moreover, studies in animals have shown that expression of a transgene from a viral vector in the liver tends to promote tolerance to the transgene product (49-52).”
BackgroundMatsushima, S. K., Shimada, Y., Kinoshita, M., Nagashima, T., Okamoto, S., Iizuka, S., Takagi, H., Iizuka, S., Higuchi, T., Hioki, H., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci180724 · Cited by 3
“Moreover, liver-directed gene therapy using AAV might induce systemic immunological tolerance to transgene products (56-59).”
Viral vectors in neurodegenerative diseases: immune responses and therapeutic applications
Wang, Y., Mu, S., & Liu, F. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1603125 · Cited by 7
Self-citationArtemyev, V., Paremskaia, A. I., Dzhioeva, A. A., Mishina, D., Bogdanov, V. P., Krupinova, J. A., Mazloum, A., Feoktistova, S. G., Mityaeva, O. N., & Volchkov, P. (2025) · Cells · doi:10.3390/cells15010014 · Cited by 4
Noncoding RNAs in Platelet Biology
Edelstein, L. C., & Bray, P. F. (2017) · Springer eBooks · doi:10.1007/978-3-319-47462-5_18 · Cited by 3
AAV Immunotoxicity: Implications in Anti-HBV Gene Therapy
Jacobs, R., Dogbey, D. M., Mnyandu, N., Neves, K., Barth, S., Arbuthnot, P. B., & Maepa, M. B. (2023) · Microorganisms · doi:10.3390/microorganisms11122985 · Cited by 3
“Evidence of the transgene products’ tolerance in the liver, induced by hepatocyte-restricted transgene expression, further supports the feasibility of AAV-mediated anti-HBV gene therapy [173,174].”
BackgroundNakai, H. (2010) · Molecular pathology library · doi:10.1007/978-1-4419-7107-4_23 · Cited by 3
Upregulation of CD8+ regulatory T cells following liver-directed AAV gene therapy
Gaddie, C. D., Senior, K. G., Chan, C. T., Hoffman, B. E., & Keeler, G. D. (2024) · Cellular Immunology · doi:10.1016/j.cellimm.2024.104806 · Cited by 2
Sakurai, F., Iizuka, S., Tsukamoto, T., Shiota, A., Shimizu, K., Ohashi, K., & Mizuguchi, H. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.08.022 · Cited by 3
Inhibitors to Factor VIII/IX: Immune Tolerance
DiMichele, D. (2010) · Wiley eBooks · doi:10.1002/9781444318555.ch10 · Cited by 3
Platelet‐directed gene therapy overcomes inhibitory antibodies to factor VIII
Chuah, M., & VandenDriessche, T. (2012) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2012.04794.x · Cited by 2
Oral Tolerance: Another Reason to Eat Your Veggies!
Hardet, R., & Mingozzi, F. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.01.001 · Cited by 2
Self-citationInhibitors to Factor VIII/IX: Immune Tolerance
DiMichele, D. (2014) · Wiley eBooks · doi:10.1002/9781118398258.ch9 · Cited by 2
Gene Therapy of Storage Disorders by Retroviral and Lentiviral Vectors
Biffi, A., & Naldini, L. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.ft-114 · Cited by 2
Adeno‐associated virus‐9 reverses delayed gastric emptying of solids in diabetic mice
Li, X., Ji, S., Cipriani, G., Hillestad, M. L., Eisenman, S. T., Barry, M. A., Nath, K. A., Linden, D. R., Wright, A. M., AlAsfoor, S., et al. (2023) · Neurogastroenterology & Motility · doi:10.1111/nmo.14669 · Cited by 2
Pichard, V., Bellodi‐Privato, M., Gournay, J., & Ferry, N. (2006) · The Journal of Gene Medicine · doi:10.1002/jgm.863 · Cited by 2
“In adult animals, the use of a liver-specific promoter to drive expression of the transgene also resulted in the absence of immune response to the transgene product after liver-directed gene delivery [17,18].”
BackgroundThe Responsible Development of Adeno-Associated Virus Gene Therapies
Wilson, J. M., & Caplan, A. L. (2025) · Human Gene Therapy · doi:10.1177/10430342251359668 · Cited by 2
“4 – 6 Prior experience with toxicity following systemic delivery of adenoviral vectors resulted in severe and potentially lethal systemic in fl ammation due to an acute activation of innate immunity.”
Käyhty, P., Nieminen, T., Eriksson, R. A. E., Tumelius, R., Tawfek, A., Laidinen, S., Ruotsalainen, A., Bailey, A., Galibert, L., Lesch, H. P., et al. (2026) · Gene Therapy · doi:10.1038/s41434-025-00588-9 · Cited by 1
“Furthermore, certain therapeutic proteins or their overexpression can also provoke immune responses [14, 16 – 18].”
Identification of alterations of immunometabolism associated with Pompe disease
Verdera, H. C., Gargaro, M., Cagin, U., Manni, G., Scalisi, G., Veron, P., Barcelos, E. C. S., Pieroni, B., Mencarelli, G., Ricciuti, D., et al. (2026) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-026-06135-y · Cited by 1
“Of note, establishment of immune tolerance to a transgene in the setting of gene therapy is key to achieving long-term efficacy in AAV gene therapy [ 90], and impairment of Treg induction has been associated with enhanced immunogenicity [91 ].”
Self-citationSaxena, H., Domenis, R., Romano, G., Biasizzo, J., Ferro, M., Ferino, D., Vicidomini, A., Iaconcig, A., Bortolussi, G., Zentilin, L., et al. (2026) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.70188 · Cited by 1
Metadata
- Authors
- Mingozzi, F., Liu, Y.-L., Dobrzynski, E., Kaufhold, A., Liu, J. H., Wang, Y., Arruda, V. R., High, K. A., & Herzog, R. W.
- Affiliations
- Children's Hospital of Philadelphia (US)
- Corresponding author
- Herzog, Roland W.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2003-05-01
- Volume
- 111
- Issue
- 9
- Pages
- 1347-1356
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC154443
- OpenAlex
- W4250446838
- Cited by
- 466
- References
- 44
- Citations by year
- 2026: 12 · 2025: 13 · 2024: 19 · 2023: 11 · 2022: 17 · 2021: 16 · 2020: 19 · 2019: 21 · 2018: 24 · 2017: 29 · 2016: 13 · 2015: 18 · 2014: 21 · 2013: 17 · 2012: 23
- FWCI
- 13.44
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Hemophilia Foundation
- Hemophilia of Georgia
- National Institutes of Health (5r01hl061921-02)
- National Heart, Lung, and Blood Institute (R01 HL61921)
- National Institute of Allergy and Infectious Diseases (R01 AI/HL 51390-01)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- immune tolerance, coagulation factor IX, AAV gene delivery, hepatic gene transfer, gene replacement therapy, hemophilia B, regulatory T cells, T cell tolerance, transgene expression, secreted antigens, humoral immune response
- MeSH terms
- Dependovirus, Animals, Antibodies, Hemophilia B, Factor IX, Humans, Immune Tolerance, Liver, Mice, Inbred Strains, Promoter Regions, Genetic, Receptors, Antigen, T-Cell, T-Lymphocytes, Genetic Therapy, Interleukin-4, Gene Transfer Techniques, Mice, Knockout, fas Receptor, Adoptive Transfer, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.